Status:
COMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
Lead Sponsor:
Queen's University
Conditions:
BPH
Eligibility:
MALE
18+ years
Brief Summary
We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated w...
Detailed Description
Histological inflammation in patients with Benign Prostatic Hyperplasia (BPH) appears to predict clinical progression and ultimate long-term response to various medical therapies, including finasterid...
Eligibility Criteria
Inclusion
- scheduled for transurethral resection of the prostate
Exclusion
- unable to give consent
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00407329
Start Date
November 1 2006
End Date
January 1 2012
Last Update
November 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Advanced Urological Research
Kingston, Ontario, Canada, K7L 3J7